Suppr超能文献

乳房切除术即刻乳房再造是否会影响辅助化疗的启动?

Does Immediate Breast Reconstruction after Mastectomy affect the Initiation of Adjuvant Chemotherapy?

机构信息

Division of Breast and Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

J Breast Cancer. 2011 Dec;14(4):322-7. doi: 10.4048/jbc.2011.14.4.322. Epub 2011 Dec 27.

Abstract

PURPOSE

The frequency of immediate breast reconstruction (IBR) is increasing, and the types of reconstruction used are diverse. Adjuvant chemotherapy is a life-saving intervention in selected high-risk breast cancer patients. The aim of our study was to determine how IBR and type of reconstruction affect the timing of the initiation of chemotherapy.

METHODS

We obtained data from female breast cancer patients treated by mastectomy with IBR (IBR group) and without IBR (mastectomy only group) who received adjuvant chemotherapy between January 1, 2008, and December 31, 2010. We retrospectively collected data including patient characteristics, disease characteristics, treatment details, and treatment outcomes from our institutional electronic patient database and medical treatment records. The reconstruction types were categorized as deep inferior epigastric perforator (DIEP) flap, latissimus dorsi (LD) flap and tissue expander/implant (TEI).

RESULTS

In total, 595 patients were included in this study. Of these patients, 43 underwent mastectomy with IBR (IBR group) and 552 patients did not undergo reconstruction (mastectomy only group). There was significant difference in the timing of the initiation of chemotherapy between the two groups (p<0.0001). There were no cases of delays of more than 12 weeks. In the IBR group, 20 patients received TEI, 9 patients were treated by the insertion DIEP flaps, and 14 patients were treated by LD flaps. There were no significant differences in the timing of chemotherapy according to the type of reconstruction (p=0.095).

CONCLUSION

IBR delays the initiation of chemotherapy, but does not lead to omission or significant clinical delay in chemotherapy. Further, the type of reconstruction does not affect the timing of chemotherapy.

摘要

目的

即刻乳房重建(IBR)的频率正在增加,所使用的重建类型也多种多样。辅助化疗是选定高危乳腺癌患者的救命干预措施。我们的研究目的是确定 IBR 和重建类型如何影响化疗的开始时间。

方法

我们从 2008 年 1 月 1 日至 2010 年 12 月 31 日期间接受 IBR(IBR 组)和未接受 IBR(仅行乳房切除术组)的女性乳腺癌患者中获得数据,这些患者接受了辅助化疗。我们从机构电子患者数据库和医疗记录中回顾性收集包括患者特征、疾病特征、治疗细节和治疗结果在内的数据。重建类型分为深部腹壁下动脉穿支(DIEP)皮瓣、背阔肌(LD)皮瓣和组织扩张器/植入物(TEI)。

结果

共有 595 例患者纳入本研究。其中 43 例行乳房切除术伴 IBR(IBR 组),552 例患者未行重建(仅行乳房切除术组)。两组化疗开始时间存在显著差异(p<0.0001)。没有超过 12 周的延迟。在 IBR 组中,20 例患者接受 TEI,9 例患者接受 DIEP 皮瓣插入,14 例患者接受 LD 皮瓣治疗。根据重建类型,化疗开始时间无显著差异(p=0.095)。

结论

IBR 会延迟化疗的开始,但不会导致化疗的遗漏或明显临床延迟。此外,重建类型不会影响化疗的时间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b8f/3268930/eb0b25744687/jbc-14-322-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验